Russian incentives to attract Japanese drugmakers to establish production

24 August 2018
russia_roubles_rubles_money_big

Russia plans to offer a special ‘green corridor’ for pharmaceutical companies from Japan that are interested in establishing production within the country, according to recent statements of Russia’s Vice Prime Minister Olga Golodets, one of the people, responsible for the development of pharmaceutical industry in the Russian government, reports The Pharma Letter’s local correspondent.

According to Ms Golodets, these corridors will ease the access of Japanese companies to the Russian pharmaceutical market and provide benefits to them in the form of taxes and customs preferences.

Earlier this year, Japanese Prime Minister Shinzo Abe had already spoken about the interest of some Japanese drugmakers to increase the supply of their drugs to the Russian market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical